NS-2359 citrate
| Code | Size | Price |
|---|
| TAR-T26364-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
NS-2359 is a serotonin-norepinephrine-dopamine reuptake inhibitor.
CAS:
195875-69-5
Formula:
C22H29Cl2NO8
Molecular Weight:
506.37
Purity:
0.98
SMILES:
OC(=O)CC(O)(CC(O)=O)C(O)=O.[H][C@]12CC[C@]([H])([C@H](COC)[C@H](C1)c1ccc(Cl)c(Cl)c1)N2C
References
1. Learned S, Graff O, Roychowdhury S, Moate R, Krishnan KR, Archer G, Modell JG, Alexander R, Zamuner S, Lavergne A, Evoniuk G, Ratti E. Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials. J Psychopharmacol. 2012 May;26(5):653-62. doi: 10.1177/0269881111424931. PubMed PMID: 22048884.
2. Wilens TE, Klint T, Adler L, West S, Wesnes K, Graff O, Mikkelsen B. A randomized controlled trial of a novel mixed monoamine reuptake inhibitor in adults with ADHD. Behav Brain Funct. 2008 Jun 13;4:24. doi: 10.1186/1744-9081-4-24. PubMed PMID: 18554401; PubMed Central PMCID: PMC2442604.